Pepper Bio is a seed-stage company based in Boston that has developed a computational platform for drug discovery. The company utilizes layers of biological data, including genetic data, proteomics, transcriptomics, and phosphoproteomics, to extract information and aid in the discovery of new drugs. Pepper Bio describes itself as a 'Waze for drug discovery' and aims to handle complex diseases by providing global causal and functional data analysis. The company has already raised a pre-seed round and is currently raising a seed round, with backing from NFX.

Jon Hu

Samantha Dale Strasser

Pepper Bio

Find new targets. Predict the best patients. Know how well new drugs will work, before you begin. 

Applying transomic technology that uses phosphoproteomic data, Pepper creates treatments for previously untreatable diseases with more informed drug discovery and development.

Reinforced Ventures

At the intersection of long term friendship, cutting-edge computational biology methods, and a deep passion for treating untreatable disease, is Pepper Bio.

Today, we’re honored and excited to officially launch out of stealth mode as the ‘Waze for drug discovery.’ As the world’s first transomics drug discovery company, Pepper Bio layers genomic, transcriptomic, and proteomic data to provide partners with the most comprehensive biotech stack – giving pharma a 3D map for their drug development pipeline.

With this technology, we’ll be able to help biopharma partners navigate around delays and costly mistakes in clinical trials to discover, rediscover, and rescue drugs that are on a course toward failing.

We’re looking forward to bringing hope to those who have none -- patients with no cure to the disease they're suffering from. 

You can read more about our journey and the ‘why’ behind Pepper Bio in Emma Betuel's exclusive story on our launch in TechCrunch: https://lnkd.in/etvXGuF2 
 
Please reach out if you’re interested in partnering with us on this mission, joining the team, or learning about how our technology will help us save pharma and patients. 

#Transomics #AI #Biotech #DrugDiscovery

🧬 Precision medicine is revolutionizing treatment approaches by tailoring them to a patient's unique genomic cancer alterations. However, this refined focus on genomics comes with challenges—specifically in determining optimal treatments and drug dosages that align with these unique genetic profiles.

A recent study from the UC San Diego Health - Moores Cancer Center discussed novel oncology drug combinations, showing promising results.

Here's where pharmacists come in—their specialized knowledge is proving invaluable in ensuring the right drug dosages, monitoring safety & efficacy, reducing drug toxicities, and even guiding patient-specific treatments in precision medicine.

Read more from Amir Ali, PharmD, BCOP and Merry Ann Sta Maria in Pharmacy Times: https://bit.ly/48YKa0h 

#PrecisionMedicine #BioTech


In the ever-evolving landscape of drug discovery, protein-based drugs are one area that promises unprecedented breakthroughs. These therapeutics offer vast potential, but here's the catch—fewer than 10% make it past clinical trials.

While AI’s prowess has been celebrated across industries, its true brilliance in drug discovery shines when paired with collective data insights. The power of one company's data can be substantial, but when combined? We’re talking seismic shifts in innovation.

It's time for the biopharmaceutical industry to rally, forming united fronts that leverage the best of collective innovation.

Learn more in Nature Portfolio: https://bit.ly/45CovrR 

CC: Marissa Mock Suzanne Edavettal Christopher Langmead Alan Russell


Navigating the intricate path from molecule concept to drug discovery can take up to 15 years and cost billions. It's no surprise that the pharmaceutical industry seeks innovations that can expedite and refine this intricate process. 

🧬 Enter AI.

Complex and time-consuming calculations, like quantum mechanics approximations or predicting binding energies, which traditionally took hours, can now be completed in milliseconds with trained AI models.

While it may be premature to claim that all future drug discoveries will solely rely on AI, it has critically impacted decision-making in drug discovery. There’s exciting work, driven by talented individuals and innovative institutions, forging ahead to make a profound impact in the field.

Matthew Habgood of Drug Target Review and Dr. Robert Scoffin have more insight on AI in drug discovery here: https://bit.ly/3rVBJlR 

#DrugDiscovery #BioTech

By integrating advanced CRISPR-Cas9 editing techniques on CD34-positive hematopoietic stem/progenitor cells, Boston Children's Hospital and Dana-Farber Cancer Institute recalibrated how immunotherapy targets AML—ensuring treatment precision without collateral damage to healthy cells.

Such advancements underscore a critical lesson—true innovation arises from discovery and continually reimagining and reshaping our approaches. 

As leaders in the healthcare space, let's champion such paradigm shifts, fostering a brighter, more effective future for patient care.

https://bit.ly/3PLRuoi

#BioTech #AML #DrugDiscovery

Metric
Company Name	Pepper Bio
Symbol
MSH ID	BIO:PEPPER
Market	PRIVATE
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	13
Website	pepper.bio
LinkedIn	pepperbio
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

BIO:PEPPER

Pepper Bio

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue